Tiny Biotech Stock Wins $75 Billion Patent

Sponsored by: Behind the Markets

Cytarbine.

That's the name of the most popular drug doctors prescribed last year to fight leukemia.

Problem is, Cytarbine is a “chemical drug” that was patented almost 60 years ago. Chemical drugs are like nuclear weapons. Drop them inside your body and everything gets destroyed. It's why people say, “the chemo will get you before the cancer does.”

It gets even worse…

75% of all cancer drugs sold by Big Pharma are old chemical drugs like Cytarbine.

Well guess what?

On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of treatment that can “Cut & Paste” any disease from your body.

It's like this tiny biotech invented the iPhone while Big Pharma is still selling flip phones.

And our research proves that anyone who gets in today could to see a 46,751% return (or more)!

The Big Pharma companies that have the most to lose from this new treatment are Bristol Meyers, Pfizer, Sanofi, Novartis and Teva.

Sanofi has their own new drug on the market. Pfizer bought Array Biopharma, which we recommended. That leaves Novartis, Teva and Bristol Meyers.

We think Bristol Meyers is the most likely buyer because their new leukemia drug flunked out of FDA trials.

A deal could happen any day.

A takeover of the company could hand investors gains of up to 31,250% in the next 90 days…

But we would be ok if there wasn't a deal.

That's because Investor's Business Daily estimates this is a $75 billion market.

Yet right now, its stock price is just a tiny fraction of that size.

CLICK HERE to see how you can profit from this rare opportunity.

$3.73 EV Stock No One's Talking About

This company is a sneaky EV play that no one’s talking about.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

53-cent Biotech Stock with $2 Price Target

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only 53 cents.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works